By otakuyassine3@gmail.com 
IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 2,810,000 shares, a decrease of 9.6% from the November 30th total of 3,110,000 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average trading volume of 1,520,000 shares, the short-interest ratio is presently 1.8 days.
Analyst Ratings Changes
Several research firms have issued reports on IQV. Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.82.
Check Out Our Latest Stock Analysis on IQV
Institutional Trading of IQVIA
Large investors have recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board raised its position in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the period. Farallon Capital Management LLC boosted its stake in shares of IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after acquiring an additional 86,870 shares in the last quarter. FMR LLC grew its holdings in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. lifted its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Finally, Impax Asset Management Group plc boosted its stake in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares during the period. 89.62% of the stock is currently owned by institutional investors.
IQVIA Price Performance
Shares of IQV stock traded down $0.94 during mid-day trading on Wednesday, hitting $196.51. 718,908 shares of the stock traded hands, compared to its average volume of 1,193,056. The company’s 50-day simple moving average is $204.17 and its 200-day simple moving average is $222.49. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The firm has a market cap of $35.67 billion, a price-to-earnings ratio of 25.79, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Receive News & Ratings for IQVIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IQVIA and related companies with MarketBeat.com’s FREE daily email newsletter.